{
  "source": "PA-Notification-Litfulo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1422-32\nProgram Prior Authorization/Notification\nMedication Litfulo™ (ritlecitinib)\nP&T Approval Date 11/2023, 12/2024\nEffective Date 3/1/2025\n1. Background:\nLitfulo (ritlecitinib) is a kinase inhibitor indicated for the treatment of severe alopecia areata in\nadults and adolescents 12 years and older.\nLimitations of Use:\nNot recommended for use in combination with other JAK inhibitors, biologic\nimmunomodulators, cyclosporine or other potent immunosuppressants\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Litfulo will be approved based on both of the following criteria:\na. Diagnosis of severe alopecia areata\n-AND-\nb. Patient is not receiving Litfulo in combination with either of the following:\n(1) Targeted immunomodulator [e.g., Olumiant (baricitinib), Enbrel (etanercept),\nCimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Rinvoq (upadacitinib)]\n(2) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Litfulo will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Litfulo therapy\n-AND-\nb. Patient is not receiving Litfulo in combination with either of the following:\n(1) Targeted immunomodulator [e.g., Olumiant (baricitinib), Enbrel (etanercept),\nCimzia (certolizumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Rinvoq (upadacitinib)]\n© 2024 UnitedHealthcare Services Inc.\n1\n(2) Potent immunosuppressant (e.g., azathioprine or cyclosporine)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initia",
    " may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits, Step Therapy, and/or Medical Necessity may be in place.\n4. References:\n1. Litfulo [package insert]. New York, NY: Pfizer, Inc.; June 2023.\nProgram Prior Authorization/Notification - Litfulo (ritlecitinib)\nChange Control\n11/2023 New program.\n12/2024 Annual review with no change to coverage criteria.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}